SCHEMBL15026848

SCHEMBL15026848

CN(C)CCCC(=O)OC(CCCCCCCCC(=O)OC1CCCCC1)CCCCCCCCC(=O)OC1CCCCC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NAAA Q02083 2/20 0.55
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ MAPT P10636 1/20 0.35
▸ MAPK1 P28482 1/20 0.35
▸ HTT P42858 1/20 0.35
▸ HDAC4 P56524 1/20 0.35
▸ HDAC1 Q13547 1/20 0.35
▸ LMNA P02545 3/20 0.34
▸ ALDH1A1 P00352 2/20 0.34
▸ SIGMAR1 Q99720 1/20 0.34
▸ DNM1 Q05193 1/20 0.34
▸ CYP2C19 P33261 1/20 0.34
▸ EPHX1 P07099 1/20 0.33
▸ KDM4E B2RXH2 1/20 0.32
▸ HPGD P15428 1/20 0.32
▸ EPHX2 P34913 1/20 0.32
▸ PRKCA P17252 1/20 0.32
▸ PRKCE Q02156 1/20 0.32
▸ PRKCQ Q04759 1/20 0.32
▸ PRKCD Q05655 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16376200 1.00 NAAA (0.55) NAAASMN1; SMN2MAPTMAPK1HTT
SCHEMBL15009576 1.00 NAAA (0.55) NAAASMN1; SMN2MAPTMAPK1HTT
SCHEMBL15027493 0.99 NAAA (0.54) NAAASMN1; SMN2MAPTMAPK1HTT
SCHEMBL15009586 0.99 NAAA (0.54) NAAASMN1; SMN2MAPTMAPK1HTT
SCHEMBL31323892 0.99 NAAA (0.52) NAAASMN1; SMN2MAPTMAPK1HTT
SCHEMBL29190226 0.95 NAAA (0.64) NAAASMN1; SMN2MAPTMAPK1LMNA
SCHEMBL15028238 0.95 NAAA (0.50) NAAASMN1; SMN2MAPTMAPK1HDAC4
SCHEMBL15028144 0.86 NAAA (0.40) NAAASMN1; SMN2MAPTMAPK1LMNA
SCHEMBL20924765 0.86 NAAA (0.58) NAAASMN1; SMN2MAPTMAPK1HTT
SCHEMBL20924712 0.85 NAAA (0.57) NAAASMN1; SMN2MAPTMAPK1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2788316-B1 BRANCHED ALKYL AND CYCLOALKYL TERMINATED BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS ALNYLAM PHARMACEUTICALS INC (US) 2019-04-24 — — EP disclosed
US-9463247-B2 Branched alkyl and cycloalkyl terminated biodegradable lipids for the delivery of active agents ALNYLAM PHARMACEUTICALS, INC. (US) 2016-10-11 — — US disclosed
US-9463247-B2 Branched alkyl and cycloalkyl terminated biodegradable lipids for the delivery of active agents ALNYLAM PHARMACEUTICALS, INC. (US) 2016-10-11 — — US disclosed
US-20150005363-A1 Branched Alkyl And Cycloalkyl Terminated Biodegradable Lipids For The Delivery Of Active Agents BANK OF AMERICA, N.A. 2015-01-01 — — US disclosed
US-20150005363-A1 Branched Alkyl And Cycloalkyl Terminated Biodegradable Lipids For The Delivery Of Active Agents BANK OF AMERICA, N.A. 2015-01-01 — — US disclosed
WO-2013086322-A1 BRANCHED ALKYL AND CYCLOALKYL TERMINATED BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS ALNYLAM PHARMACEUTICALS, INC. (US) 2013-06-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150005363-A1 Branched Alkyl And Cycloalkyl Terminated Biodegradable Lipids For The Delivery Of Active Agents LIPA, CETP, APOB NAAA 1178/4885SMN1; SMN2 2502/4885MAPT 3622/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback